NCT06585488 2026-03-18
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
9 trialsNCT07462442 2026-03-10
Study of QLS5308 in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT07108114 2026-02-23
SLV-324 Treatment of Metastatic Solid Tumors
Solve Therapeutics
Phase 1 Recruiting
NCT07333664 2026-01-12
Image-Guided 125I Seed Implantation Plus Standard Systemic Therapy for Patients With Multiple Metastatic Lesions
Jinan Military General Hospital
Phase 2 Not yet recruiting
NCT03388632 2025-12-18
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT07272590 2025-12-09
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07087197 2025-12-08
A Study of SKB107 in Advanced Solid Tumors With Bone Metastases
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT07249892 2025-11-25
A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases
Chengdu Syncor Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT04319198 2025-09-30
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
Phase 4 Completed